K
Kathleen E. Corey
Researcher at Harvard University
Publications - 179
Citations - 6415
Kathleen E. Corey is an academic researcher from Harvard University. The author has contributed to research in topics: Nonalcoholic fatty liver disease & Medicine. The author has an hindex of 34, co-authored 147 publications receiving 3966 citations. Previous affiliations of Kathleen E. Corey include University of North Carolina at Chapel Hill & China Medical University (PRC).
Papers
More filters
Journal ArticleDOI
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Zobair M. Younossi,Rohit Loomba,Mary E. Rinella,Elisabetta Bugianesi,Giulio Marchesini,Brent A. Neuschwander-Tetri,Lawrence Serfaty,Francesco Negro,Stephen H. Caldwell,Vlad Ratziu,Kathleen E. Corey,Scott L. Friedman,Manal F. Abdelmalek,Stephen A. Harrison,Arun J. Sanyal,Joel E. Lavine,Philippe Mathurin,Michael Charlton,Naga Chalasani,Quentin M. Anstee,Kris V. Kowdley,Jacob George,Zachary Goodman,Keith D. Lindor +23 more
TL;DR: Over the next 5 years, some of these regimens are expected to provide potential new treatment options for patients with NASH/NAFLD, and several important secondary endpoints, including noninvasive biomarkers, long‐term outcomes, and patient‐reported outcomes must be considered.
Journal ArticleDOI
Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis
Xiaobo Wang,Ze Zheng,Jorge Matias Caviglia,Kathleen E. Corey,Tina M. Herfel,Bishuang Cai,Ricard Masia,Raymond T. Chung,Jay H. Lefkowitch,Robert F. Schwabe,Ira Tabas +10 more
TL;DR: It is shown that the transcription regulator TAZ (WWTR1) is markedly higher in hepatocytes in human and murine NASH liver than in normal or steatotic liver, and represents a previously unrecognized factor that contributes to the critical process of steatosis-to-NASH progression.
Journal ArticleDOI
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis
Zobair M. Younossi,Rohit Loomba,Quentin M. Anstee,Mary E. Rinella,Elisabetta Bugianesi,Giulio Marchesini,Brent A. Neuschwander-Tetri,Lawrence Serfaty,Francesco Negro,Stephen H. Caldwell,V. Ratziu,Kathleen E. Corey,Scott L. Friedman,Manal F. Abdelmalek,Stephen A. Harrison,A. Sanyal,Joel E. Lavine,Philippe Mathurin,Michael Charlton,Zachary Goodman,N. Chalasani,Kris V. Kowdley,Jacob George,Keith D. Lindor +23 more
TL;DR: A number of noninvasive modalities to diagnose NASH and stage liver fibrosis are being developed as mentioned in this paper, including predictive models (NAFLD fibrosis score) and serum biomarkers such as enhanced Liver fibrosis (ELF), which are used to estimate liver stiffness as a potential surrogate of hepatic fibrosis.
Journal ArticleDOI
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
TL;DR: The link between NAFLD and type 2 diabetes mellitus (T2DM) is known to frequently coexist and act synergistically to increase the risk of adverse clinical outcomes as discussed by the authors.
Journal ArticleDOI
Secondary causes of nonalcoholic fatty liver disease
TL;DR: Rare but important causes of nonalcoholic fatty liver disease are discussed, including inborn errors of metabolism, iatrogenic causes, viral hepatitis, and nutritional disorders to provide practicing clinicians with an understanding of the less well recognized causes.